Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9149(90)90945-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and Angiotensin Receptor-neprylisin Inhibitors in Acute Heart Failure (PENTA-HF).
Curr Vasc Pharmacol
January 2025
IRCCS San Raffaele Cassino, 03043, Cassino, Italy.
Purpose: The management of acute heart failure (AHF) is crucial and challenging. Regarding the use of inotropes, correct patient selection and time of administration are of the essence. We hypothesize that the early use of Levosimendan favouring hemodynamic stabilization and enables rapid optimization of guideline-directed medical treatment (GDMT) in patients with HF, eventually impacting the patient's prognosis during the vulnerable phase.
View Article and Find Full Text PDFApplication of Perclose ProGlide closure device in transbrachial endovascular intervention.
Sci Rep
January 2025
Department of Cardiology, Peking University International Hospital, Peking University, Beijing, 102206, China.
This study aims to assess the clinical efficacy and feasibility of the Perclose ProGlide Suture-Mediated Closure System (Abbott Vascular, Redwood City, CA, USA) for transbrachial access. A total of 100 patients from July 2020 to December 2023 were included in this retrospective study. Among them, 40 patients underwent ProGlide-guided suture closure following brachial artery (BA) puncture, while 60 patients received traditional manual compression.
View Article and Find Full Text PDFClinical Outcomes with High- versus Low-Dose Tranexamic Acid Infusion in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.
Thorac Cardiovasc Surg
January 2025
Department of Medicine, MedStar Health, Baltimore, Maryland, United States.
Objectives: Antifibrinolytics, such as tranexamic acid (TXA), are widely used in cardiac surgery to reduce bleeding risks; however, the optimal dosage for TXA infusion remains a subject of debate. Hence, this study aims to evaluate the safety and efficacy of high-dose compared with low-dose TXA infusion in cardiac surgery patients.
Methods: PubMed, SCOPUS, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched until June 10, 2023, for studies assessing efficacy outcomes (e.
Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity.
Sci Adv
January 2025
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
A major limiting factor in the success of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors is targeting tumor antigens also found on normal tissues. CAR T cells against GD2 induced rapid, fatal neurotoxicity because of CAR recognition of GD2 normal mouse brain tissue. To improve the selectivity of the CAR T cell, we engineered a synthetic Notch receptor that selectively expresses the CAR upon binding to P-selectin, a cell adhesion protein overexpressed in tumor neovasculature.
View Article and Find Full Text PDFHSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
Blood
January 2025
Hospital Santa Creu i Sant Pau, Barcelona, Spain.
CD30-directed CART cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the non-soluble part of CD30, and the manufacturing process includes a modulation of ex vivo T cell activation, as well as the addition of interleukin-21 to IL-7 and IL-15 to promote stemness of T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!